The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Expanded Screening for HIV in the United States — An Analysis of Cost-Effectiveness
Open accessAbstract
BACKGROUND: Although the Centers for Disease Control and Prevention (CDC) recommend routine HIV counseling, testing, and referral (HIVCTR) in settings with at least a 1 percent prevalence of HIV, roughly 280,000 Americans are unaware of their human immunodeficiency virus (HIV) infection. The effect of expanded screening for HIV is unknown in the era of effective antiretroviral therapy. METHODS: We developed a computer simulation model of HIV screening and treatment to compare routine, voluntary HIVCTR with current practice in three target populations: "high-risk" (3.0 percent prevalence of undiagnosed HIV infection; 1.2 percent annual incidence); "CDC threshold" (1.0 percent and 0.12 percent, respectively); and "U.S. general" (0.1 percent and 0.01 percent). Input data were derived from clinical trials and observational cohorts. Outcomes included quality-adjusted survival, cost, and cost-effectiveness. RESULTS: In the high-risk population, the addition of one-time screening for HIV antibodies with an enzyme-linked immunosorbent assay (ELISA) to current practice was associated with earlier diagnosis of HIV (mean CD4 cell count at diagnosis, 210 vs. 154 per cubic millimeter). One-time screening also improved average survival time among HIV-infected patients (quality-adjusted survival, 220.7 months vs. 219.8 months). The incremental cost-effectiveness was 36,000 dollars per quality-adjusted life-year gained. Testing every five years cost 50,000 dollars per quality-adjusted life-year gained, and testing every three years cost 63,000 dollars per quality-adjusted life-year gained. In the CDC threshold population, the cost-effectiveness ratio for one-time screening with ELISA was 38,000 dollars per quality-adjusted life-year gained, whereas testing every five years cost 71,000 dollars per quality-adjusted life-year gained, and testing every three years cost 85,000 dollars per quality-adjusted life-year gained. In the U.S. general population, one-time screening cost 113,000 dollars per quality-adjusted life-year gained. CONCLUSIONS: In all but the lowest-risk populations, routine, voluntary screening for HIV once every three to five years is justified on both clinical and cost-effectiveness grounds. One-time screening in the general population may also be cost-effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Statistical Abstract of the United States
(2005) · Encyclopedia of Statistical Sciences · doi:10.1002/0471667196.ess2527 · Cited by 8,785
Cost-Effectiveness in Health and Medicine
(1996) · doi:10.1093/oso/9780195108248.001.0001 · Cited by 7,193
Hammer, S. M., Squires, K. E., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J. E., Balfour, H. H., Deyton, L. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,640
Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection
Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-12-199706150-00003 · Cited by 2,067
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Masur, P. B. H., Kaplan, J. E., & Holmes, K. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00002 · Cited by 567
The Care of HIV-Infected Adults in the United States
Bozzette, S. A., Berry, S. H., Duan, N., Frankel, M. R., Leibowitz, A. A., Lefkowitz, D., Emmons, C.-A., Senterfitt, J. W., Berk, M. L., Morton, S. C., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812243392606 · Cited by 508
The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease
Freedberg, K. A., Losina, E., Weinstein, M. C., Paltiel, A. D., Cohen, C. J., Seage, G. R., Craven, D. E., Zhang, H., Kimmel, A. D., & Goldie, S. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441108 · Cited by 508
Self-citationBaxter, J. D., Mayers, D. L., Wentworth, D. N., Neaton, J. D., Hoover, M. L., Winters, M. A., Mannheimer, S., Thompson, M., Abrams, D. I., Brizz, B., et al. (2000) · AIDS · doi:10.1097/00002030-200006160-00001 · Cited by 494
Guide to Clinical Preventive Services: Report of the U S Preventive Services Task Force
U.S. Preventive Services Task Force (1996) · Medical Entomology and Zoology · Cited by 446
Guide to clinical preventive services. Report of the US Preventive Services Task Force.
Tw, A. (1991) · PubMed · Cited by 174
Schackman, B. R., Goldie, S. J., Freedberg, K. A., Losina, E., Brazier, J. E., & Weinstein, M. C. (2002) · Medical Decision Making · doi:10.1177/0272989x0202200103 · Cited by 110
Self-citationAre US Populations Appropriate for Trials of Human Immunodeficiency Virus Vaccine?
Seage, G. R., Holte, S., Metzger, D. S., Koblin, B. A., Gross, M., Celum, C., Marmor, M. F., WOODY, G. E., Mayer, K. H., Stevens, C. E., et al. (2001) · American Journal of Epidemiology · doi:10.1093/aje/153.7.619 · Cited by 110
Self-citationCost comparison of three HIV counseling and testing technologies
Ekwueme, D. U., Pinkerton, S. D., Holtgräve, D. R., & Branson, B. M. (2003) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(03)00115-6 · Cited by 93
Walensky, R. P., Losina, E., Malatesta, L., Barton, G. E., O’Connor, C. A., Skolnik, P. R., Hall, J. M., McGuire, J. F., & Freedberg, K. A. (2005) · American Journal of Public Health · doi:10.2105/ajph.2003.031310 · Cited by 83
Self-citationBlood pressure and body measurements among Navajo adolescents.
Farnham, P. G., Gorsky, R. D., Holtgrave, D. R., Jones, W. K., & Guinan, M. E. (1996) · Europe PMC (PubMed Central) · Cited by 80
Tracking the HIV epidemic: current issues, future challenges
Fleming, P. L., WORTLEY, P. M., Karon, J. M., DeCock, K. M., & Janssen, R. S. (2000) · American Journal of Public Health · doi:10.2105/ajph.90.7.1037 · Cited by 74
Webster, R. D., Darrow, W. W., Paul, J. P., Roark, R. A., Woods, W. J., & Stempel, R. R. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200306010-00018 · Cited by 34
Bos, J. M., van der Meijden, W. I., Swart, W., et al. (2002) · AIDS · doi:10.1097/00002030-200205240-00015 · Cited by 14
Cited by
(2006) · PsycEXTRA Dataset · doi:10.1037/e545592006-001 · Cited by 2,958
Weinbaum, C. M., Mast, E. E., & Ward, J. W. (2009) · Hepatology · doi:10.1002/hep.22882 · Cited by 815
Eddy, D. M., Hollingworth, W., Caro, J. J., Tsevat, J., McDonald, K. M., & Wong, J. B. (2012) · Medical Decision Making · doi:10.1177/0272989x12454579 · Cited by 799
The Survival Benefits of AIDS Treatment in the United States
Walensky, R. P., Paltiel, A. D., Losina, E., Mercincavage, L. M., Schackman, B. R., Sax, P. E., Weinstein, M. C., & Freedberg, K. A. (2006) · The Journal of Infectious Diseases · doi:10.1086/505147 · Cited by 581
Self-citationEvidence-based clinical guidelines for immigrants and refugees
Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N. E., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 526
Metadata
- Authors
- Paltiel, A. D., Weinstein, M. C., Kimmel, A. D., Seage, G. R., Losina, E., Zhang, H., Freedberg, K. A., & Walensky, R. P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-02-10
- Volume
- 352
- Issue
- 6
- Pages
- 586-595
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2060057531
- Cited by
- 553
- References
- 21
- FWCI
- 30.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.